Mesoblast Limited
MEOBF
$1.90
$0.2515.15%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 120.25M | 92.82M | 65.38M | 41.29M | 17.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 120.25M | 92.82M | 65.38M | 41.29M | 17.20M |
| Cost of Revenue | 24.03M | 45.16M | 66.30M | 41.96M | 17.62M |
| Gross Profit | 96.22M | 47.65M | -914.00K | -666.50K | -419.00K |
| SG&A Expenses | 57.35M | 53.59M | 49.84M | 44.57M | 39.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -22.00K | -1.16M | -2.29M | -949.50K | 395.00K |
| Total Operating Expenses | 171.50M | 153.83M | 136.16M | 107.90M | 79.64M |
| Operating Income | -51.25M | -61.01M | -70.78M | -66.61M | -62.44M |
| Income Before Tax | -56.89M | -75.35M | -93.81M | -97.81M | -101.81M |
| Income Tax Expenses | 613.00K | 588.00K | 563.00K | 446.50K | 330.00K |
| Earnings from Continuing Operations | -57.50 | -75.94 | -94.37 | -98.26 | -102.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.50M | -75.94M | -94.37M | -98.26M | -102.14M |
| EBIT | -51.25M | -61.01M | -70.78M | -66.61M | -62.44M |
| EBITDA | -45.01M | -54.67M | -64.34M | -61.26M | -58.18M |
| EPS Basic | -0.04 | -0.06 | -0.07 | -0.08 | -0.08 |
| Normalized Basic EPS | -0.03 | -0.04 | -0.04 | -0.04 | -0.05 |
| EPS Diluted | -0.04 | -0.06 | -0.07 | -0.08 | -0.08 |
| Normalized Diluted EPS | -0.03 | -0.04 | -0.04 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 5.18B | 5.16B | 5.13B | 4.98B | 4.83B |
| Average Diluted Shares Outstanding | 5.18B | 5.16B | 5.13B | 4.98B | 4.83B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |